Empowering resilience in Mozambique under the America First Global Health Strategy Press Statement Thomas "Tommy" Pigott, Principal Deputy Spokesperson at the U ...

Zimbabwe is preparing to place at least 46 500 people on a long-acting HIV prevention drug early next year marking the country's first rollout of Lenacapavir a twice-yearly injectable that offers ...

In the study, a once-daily, single-tablet combination of bictegravir and lenacapavir was as effective as Gilead's existing ...

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

The Herald (Top Stories) Rumbidzayi Zinyuke recently in ACCRA, Ghana AT LEAST 46 500 people will be put on the long-acting HIV prevention drug Lenacapavir early next year, as Zimbabwe begins its first ...

Over 46 000 high-risk individuals to receive long-acting HIV prevention drug | The Herald (Top Stories) Rumbidzayi Zinyuke ...

This study investigates how the HIV inhibitor lenacapavir influences capsid mechanics and interactions with the nuclear pore complex. It provides important insights into how drug-induced ...

The NHI is designed to advance South Africa’s progress toward Universal Health Coverage by ensuring equitable access to ...